Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Volume 9 Supplement 2

AIDS Vaccine 2012

Oral presentation | Open | Published:

Vaccine responses to conserved regions of the HIV-1 proteome are associated with an increased capacity to inhibit multiple virus isolates ex vivo


The majority of assays currently used to assess HIV-1 vaccine candidate immunogenicity in humans fail to predict protection against HIV-1 acquisition or control of viraemia. However, a correlation between in vivo and ex vivo control mediated by CD8+ T-cell populations has been described using an ex vivo virus inhibition assay (VIA) in chronically infected individuals and vaccinated non-human primates. Here we attempt to relate the specificity of vaccine-induced virus-specific CD8 responses to the inhibition of HIV-1 ex vivo.


Using peptide epitope mapping, we assessed the breadth and specificity of CD8 T-cell responses induced by vaccination using two adenovirus serotype 35 (Ad35) vectors containing gag, reverse transcriptase, integrase and nef (Ad35-GRIN) and env (Ad35-ENV), respectively, derived from HIV-1 subtype A isolates. The conserved regions targeted by these 25 subjects were related to the capacity of vaccine-induced CD8 T-cells to inhibit replication of a cross-clade panel of HIV-1 isolates using the VIA.


A median of 4 peptides were recognised in vaccinated individuals (range 1-9). When related to the log reduction of p24 production as measured in the VIA, mapping data suggest that targeting immunodominant responses towards highly conserved regions of the HIV-1 proteome tended towards an increased ability to inhibit multiple clades of HIV-1 ex vivo.


These data support the plausibility of inducing conserved CD8+ T cell responses using a consensus HIV-1 subtype A sequence in an adenovirus-based vector.

Author information

Correspondence to A Ashraf.

Rights and permissions

Reprints and Permissions

About this article


  • Peptide Epitope
  • Vaccine Response
  • Adenovirus Serotype
  • Multiple Clade
  • Immunodominant Response